ClearPoint Neuro Stock Slides on Wider FY Loss

Dow Jones03-19

By Kelly Cloonan

Shares of ClearPoint Neuro declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead.

The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year.

For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier.

Revenue rose 18% to $37 million, driven by higher product revenue.

For the full year, the company is guiding for revenue of $52 million to $56 million.

The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year.

It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the ClearPoint said.

"Our company has never been in a stronger position than we are right now," Chief Executive Joe Burnett said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 18, 2026 12:57 ET (16:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620607263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620607263","market":"us","top_or_hot":-1,"title":"ClearPoint Neuro Stock Slides on Wider FY Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead. \n</p>\n<p>\n  The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year. \n</p>\n<p>\n  For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 18% to $37 million, driven by higher product revenue. \n</p>\n<p>\n  For the full year, the company is guiding for revenue of $52 million to $56 million. \n</p>\n<p>\n  The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year. \n</p>\n<p>\n  It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the ClearPoint said. \n</p>\n<p>\n  \"Our company has never been in a stronger position than we are right now,\" Chief Executive Joe Burnett said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2026 12:57 ET (16:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ClearPoint Neuro Stock Slides on Wider FY Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearPoint Neuro Stock Slides on Wider FY Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-19 00:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead. \n</p>\n<p>\n  The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year. \n</p>\n<p>\n  For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 18% to $37 million, driven by higher product revenue. \n</p>\n<p>\n  For the full year, the company is guiding for revenue of $52 million to $56 million. \n</p>\n<p>\n  The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year. \n</p>\n<p>\n  It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the ClearPoint said. \n</p>\n<p>\n  \"Our company has never been in a stronger position than we are right now,\" Chief Executive Joe Burnett said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2026 12:57 ET (16:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620607263","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620607263","pubTimestamp":1773853020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ClearPoint Neuro declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead.The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year.For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier.Revenue rose 18% to $37 million, driven by higher product revenue.For the full year, the company is guiding for revenue of $52 million to $56 million.The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year.It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the Clear","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","CLPT":"ClearPoint Neuro, Inc."},"translate_title":"ClearPoint Neuro股价因财年亏损扩大而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLPT":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of ClearPoint Neuro declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead. \n\n\n  The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year. \n\n\n  For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier. \n\n\n  Revenue rose 18% to $37 million, driven by higher product revenue. \n\n\n  For the full year, the company is guiding for revenue of $52 million to $56 million. \n\n\n  The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year. \n\n\n  It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the ClearPoint said. \n\n\n  \"Our company has never been in a stronger position than we are right now,\" Chief Executive Joe Burnett said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 12:57 ET (16:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620607263","isCrawlerRequest":true}